Efficacy and Safety between Insulin Glargine Products (LY2963016 and Lantus®) in Patients with T2DM: The ELEMENT 5 Study

被引：0
|
作者：
Pollom, Robyn K.
Lacaya, Lyndon B.
Ilag, Liza L.
机构：
来源：
DIABETES | 2017年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
963-P
引用
收藏
页码：A249 / A249
页数：1
相关论文
共 50 条
  • [31] Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed-Ratio Combination vs. Insulin Glargine in Patients with T2DM: The Lixi-Lan-L Trial
    Aroda, Vanita
    Rosenstock, Julio
    Wysham, Carol
    Unger, Jeffrey
    Bellido, Diego
    Galvez, Guillermo Gonzalez
    Takami, Akane
    Guo, Hailing
    Niemoeller, Elisabeth
    Souhami, Elisabeth
    Bergenstal, Richard M.
    DIABETES, 2016, 65 : A62 - A63
  • [32] Efficacy and safety of the insulin glargine/lixisenatide fixed-ratio combination versus insulin glargine in patients with T2DM: the LixiLan-L trial (NCT02058160).
    Aroda, Vanita
    Rosenstock, Julio
    Wysham, Carol
    Unger, Jeffrey
    Bellido, Diego
    Gonzalez-Galvez, Guillermo
    Guo, Hailing
    Takami, Akane
    Niemoeller, Elisabeth
    Souhami, Elisabeth
    Bergenstal, Richard
    PHARMACOTHERAPY, 2016, 36 (12): : E231 - E231
  • [33] Efficacy and Safety of MK-1293 Insulin Glargine Compared with Originator Insulin Glargine (Lantus) in Type 2 Diabetes (T2D)
    Hollander, Priscilla
    Golm, Gregory
    Carofano, Wendy
    Eldor, Roy
    Crutchlow, Michael
    Marcos, Michael
    Rendell, Marc
    Home, Philip
    Gallwitz, Baptist
    Rosenstock, Julio
    DIABETES, 2016, 65 : A238 - A238
  • [34] Efficacy and Safety of Dulaglutide Versus Insulin Glargine in Chinese T2DM Patients: A Subgroup Analysis of a Randomized Trial (AWARD-CHN2)
    Li, Yan
    Li, Ling
    Peng, Yong De
    Song, Guang Yao
    Ye, Shan Dong
    Du, Li Ying
    Hou, Jia Ning
    Ji, Qiu He
    DIABETES THERAPY, 2019, 10 (04) : 1435 - 1452
  • [35] Efficacy and Safety of Dulaglutide Versus Insulin Glargine in Chinese T2DM Patients: A Subgroup Analysis of a Randomized Trial (AWARD-CHN2)
    Yan Li
    Ling Li
    Yong De Peng
    Guang Yao Song
    Shan Dong Ye
    Li Ying Du
    Jia Ning Hou
    Qiu He Ji
    Diabetes Therapy, 2019, 10 : 1435 - 1452
  • [36] Once daily insulin-glargine (LANTUS®, GLAR) initiated in groups, with metformin (MET) is a practical and effective regimen in T2DM
    Gallen, IW
    Carter, C
    DIABETES, 2005, 54 : A561 - A561
  • [37] Indirect treatment comparison of efficacy and safety of insulin glargine 300 U/mL with once-daily-insulin premix in T2DM
    Ritzel, R.
    Ghosh, S.
    Emral, R.
    Malek, R.
    Malik, R.
    Zeng, L.
    Huang, Y.
    Mabunay, M. A.
    Landgraf, W.
    Guyot, P.
    Schenk, E.
    Pushkarna, D.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 186
  • [38] Effects of Metformin and Sulfonylurea on Efficacy and Hypoglycemia After Addition of Insulin Glargine or NPH in T2DM
    Bretzel, Reinhard
    Traylor, Louise
    Landgraf, Wolfgang
    DIABETES, 2014, 63 : A237 - A238
  • [39] Efficacy and safety of insulin glargine added to ongoing therapy with multiple oral antidiabetic drugs (OADs) in patients with type 2 diabetes mellitus (T2DM)
    Raskin, P.
    Tanenberg, R. J.
    Vlajnic, A.
    Hollander, P.
    DIABETOLOGIA, 2007, 50 : S405 - S406
  • [40] Influence of Gender on Glycemic Control and Hypoglycemia in T2DM Patients Initiating Insulin Glargine
    Kautzky-Willer, Alexandra
    Traylor, Louise
    Landgraf, Wolfgang
    Charbonnel, Bernard
    DIABETES, 2015, 64 : A257 - A257
12345